Objectives. Presenter Disclosure Information 11/29/2016
|
|
- Suzanna Charleen Foster
- 5 years ago
- Views:
Transcription
1 Current State of Neurosurgical Treatment of Cerebral Glioma and Clinical Trials Testing Future Advances John D. Heiss, M.D. Chair, Surgical Neurology Branch, NINDS, National Institutes of Health Presenter Disclosure Information John D. Heiss, M.D. Title: Current State of Neurosurgical Treatment of Cerebral Glioma and Clinical Trials Testing Future Advances Research Support: This work was supported by the Intramural Research Program of the National Institute of Neurological Disorders and Stroke, National Institutes of Health. All Unlabeled/Unapproved Uses are Disclosed as Such. Objectives Upon completion of my presentation, participants should be better able to: 1. Describe standard treatment for glioblastoma 2. Describe the impact of surgical neurological deficit and extent of resection on patient survival in glioblastoma 3. Describe the impact of functional brain mapping on surgical outcome and long-term prognosis in different types and grades of glioma 4. Name a few agents and methods that are being tested in glioma clinical trials 1
2 Role of Radiotherapy in Glioblastoma Treatment Radiation dose correlates with Survival Time (mean) 0 rad 18 weeks 5000 rad 28 weeks 5500 rad 36 weeks 6000 rad 42 weeks 6 month (24 week) radiation treatment effect on survival Walker MD, Strike TA, Sheline GE: An analysis of doseeffect relationship in the radiotherapy of malignant gliomas. Int J Radiation Oncology Biol. Phys. 1979; 5: Standard Glioblastoma (GBM) Treatment 573 patients with glioblastoma 286 radiotherapy* 287 radiotherapy* plus temozolomide Prior surgical procedure 84% debulking surgery 40% complete resection 44% partial resection 16% biopsy Median survival Radiotherapy plus temozolomide 14.6 months Radiotherapy alone 12.1 months Stupp R, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. NEJM 2005; 352(10): *Radiotherapy 60g over 6 weeks to gross tumor volume with 2-3 cm margin for the clinical target volume Temozolomide, 75 mg per square meter per day, 7 days per week during radiotherapy period (no more than 49 days), followed by a 4 week break, and then adjuvant dosing at mg per square meter per day for 5 days every 28 days Standard Glioma Surgery Surgical procedure selected that makes the diagnosis and removes tumor tissue from non-eloquent brain areas 1) Preserving neurological function 2) Preserving survival quality 3) Maximal tumor removal from non-eloquent areas a) Complete excision with Grade I Tumors b) Maximal cytoreduction with Grade II-IV (infiltrative) tumors Choice of surgical procedures include a) Biopsy 16% of patients (Stupp 2005 study) b) Debulking 84% of patients (Stupp 2005 study) a) Partial resection 44% b) Complete (MRI) resection 40% 2
3 Extensive surgery for glioblastoma Extensive tumor resection improves Survival time (treatment effect about 5 months) 7.5 months extensive resection & post-operative radiation 2.5 months limited resection & post-operative radiation Quality of Survival Proportion of excellent or good condition patients increases after surgery in patients with extensive resections Removes tumor mass effect Reverses ICP elevation Jelsma R, Bucy PC. Glioblastoma multiforme: its treatment and some factors effecting survival. Arch Neurol 1969 Feb;20 (2): Non-central GBM location associated with greater tumor resection, survival time & quality Central vs. non-central tumor Survival time (6.5 months longer in noncentral vs. central tumors) 10.5 months non-central tumors 4.0 months central tumors Quality of Survival Proportion of excellent or good condition patients much better in patients with tumor outside the central area comprising the precentral gyri, Broca s area, or the Sylvian fissure of the dominant hemisphere. Jelsma R, Bucy PC. Glioblastoma multiforme: its treatment and some factors effecting survival. Arch Neurol 1969 Feb;20 (2): Longer survival with more tumor debulking, better WHO performance status, & corticosteroid independence 573 patients with glioblastoma 286 radiotherapy 287 radiotherapy plus temozolomide Median overall survival months longer in the patients with tumor debulking compared to biopsy only Patients not requiring baseline steroids survived months longer than patients requiring steroids Stupp R, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. NEJM 2005; 352(10):
4 Brain Tumor WHO Grade Prognostic impact of extent of resection I Neuronal DNET Ganglioglioma Pilocytic astrocytoma II Low grade astrocytoma & oligodendroglioma III Anaplastic astrocytoma & oligodendroglioma IV Glioblastoma multiforme Invasive No Complete Resection Possible Yes; if outside eloquent structures Life Expectancy (Months) Biopsy Life Expectancy (Months) MR Incomplete Resection Life Expectancy (Months) MR Complete Resection Increased Life Expectancy (Months) with MR- Complete Resection Prolonged Prolonged Prolonged Residual tumors require additional surgery Yes No * Yes No * Yes No * *Sinai N, Berger MS: Glioma extent of resection and its impact on patient outcome. Neurosurgery 62: , 2008 Stupp R, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. NEJM 2005; 352(10): Surgically-Induced Neurological Deficit in GBM 306 consecutive patients with newly diagnosed GBM y.o. Good performance status (KPS ) Retrospective review 15 patients (5%) with new language deficit perioperatively 9.6 month median survival 19 patients (6%) with new motor deficit perioperatively 9.0 month median survival 272 patients without neurological deficits (89%) 12.8 month median survival A permanent deficit reduced quality of life immediately and shortened survival by 3-4 months compared to patients without deficits. McGirt MJ, Mukherjee D, Chaichana KL, Than KD, Weingart JD, Quinones-Hinojosa A. Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery. 2009; 65: Maximizing Tumor Removal from Non-Eloquent Brain Remove all tumor from non-eloquent areas Establish non-eloquent margins by functional brain mapping and anatomic MRI Avoid injury to eloquent brain areas Direct injury Eloquent brain area mapping Eloquent cerebral cortex Subcortical white matter tracts Secondary injury Anatomic knowledge and MRI Arteries Local vessels Arteries of passage Major veins Vein of Labbé Figure from: Hervey- Jumper SL, Berger MS: Maximizing safe resection of low- and high-grade glioma. J Neurooncol (2016) 130:
5 Intraoperative Electrical Mapping Hughes Duffau: Intraoperative electrical mapping of eloquent cortical and white matter pathways is the standard of care for supratentorial glioma surgery, particularly for tumors adjacent to eloquent brain Acta Neurochir (Wien) 155:1803-4, 2013 Fewer permanent neurologic deficits (2-3.5%) More extensive resection Anesthetic technique Duffau (2013): Asleep-awake-asleep Patient asleep for opening & last part of resection and closure Pain range on 0-10 analogue scale Anxiety Sanai, Mirzadeh, Berger (2008): Sedation-awake-sedation Hansen et al. (2013): Awake-awake-awake Patient awake entire procedure 2/3rds of patients requested remifentanil No sedation needed except for seizures Therapeutic communication between anesthesiologist and patient Intraoperative Stimulation Mapping Identifies regions of eloquent function during surgery Craniotomy with mapping under local anesthesia using electrical cortical stimulation Positive effects of stimulation Motor cortex--movement Somatosensory cortex--localized dysesthesias Negative effects of stimulation Language--Disruption of language task Memory--Disruption of memory task Maintain a Margin of Safety Between Resection and Language Sites Cortical Localization of Temporal Lobe Language Sites in Patients with Gliomas. Haglund, Michael; Berger, Mitchel; Shamseldin, Michael; Lettich, Etorre; Ojemann, George Neurosurgery. 34(4): , April Figure 5. The distance of the resection margin to the nearest language site is analyzed with regard to the number of days a language deficit is present after tumor removal. Error bars represent the standard error of the mean. Copyright by the Congress of Neurological Surgeons. Published by Lippincott Williams & Wilkins, Inc. 2 5
6 Intraoperative Language Mapping Sanai N, Mirzadeh Z, Berger MS: Functional outcome after language mapping for glioma resection. N Engl J Med 358:18-27, 2008 Method: 250 consecutive glioma cases Intraoperative electrical stimulation mapping to identify language areas Resection of tumor up to 1 cm away from cortical areas that demonstrated language disturbance with electrical stimulation Results A total of 145 of the 250 patients (58.0%) had at least one site with an intraoperative stimulation-induced speech arrest, 82 patients had anomia, and 23 patients had alexia. Overall, 3094 of 3281 cortical sites (94.3%) were not associated with stimulation induced language deficits. A total of 159 patients (63.6%) had intact speech preoperatively. One week after surgery, baseline language function remained in 194 patients (77.6%), it worsened in 21 patients (8.4%), and 35 patients (14.0%) had new speech deficits. However, 6 months after surgery, only 4 of 243 surviving patients (1.6%) had a persistent language deficit. GTR (MRI) in 51.6% Grade I & II tumors; 65% Grade III tumors; 69% Grade IV tumors Intraoperative MRI guidance to highlight tumor Adjunct measure to identify more high-grade glioma tissue during the operative procedure Assessment Trend toward imri increasing tumor removal from non-eloquent brain Randomized trial of 58 patients with high-grade glioma* (All Grade 3 or 4, except for 1 ganglioglioma in the MRI groups) Microsurgery imri guided Gross total resection 68% 96% (p=0.023) Progression free survival 154 days 226 days (p=0.083) No apparent effect on neurological funcron Preserves survival quality No difference in SAEs and AE between 2 groups *Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V: Intraoperative MRI guidance and extend of resection in glioma surgery: a randomized, controlled trial. Lancet Oncol 2011 OCT; 12: Cortical Mapping in the IMR Suite 6
7 Cortical Mapping in the imri Imaging Suite Operating Outside the 5G Field Operative Procedure A) MR-Compatible 3-pin head holder that extends off the table; Surface coil between head holder and head; B) MR-compatible patient reference frame; C) MR-imaging coil wrapped in sterile plastic sheet and placed around surgical field; D) Position in MRscanner 7
8 Graduate student with new onset of complex partial seizures T1 -Weighted Image T2-Weighted Images Left Temporal Lobe Tumor Modified from Figure in Hansebout RR: Surgery of epilepsy current technique of cortical resection. In: Schmidek HH & Sweet WH, eds. Operative Neurosurgical Techniques: Indications, Methods, and Results. 2nd ed. New York: WB Saunders Co., Cortical stimulation testing: Mandarin primary, English second language;1,2: Sensation in Mouth; 21: Broca s area; 24: Wernicke s area in English; 23-27: Wernicke s area in Mandarin; Letters: Negative Stimulation imri Guides Tumor Resection Before Craniotomy After Initial Resection 6 Months After Surgery 8
9 57 year old woman with partial seizures Pre T1 With Gd Superior temporal gyrus tumor Inferior Ant. Negative Stimulation: Letters Broca s Area: 20, 24, 26 Mouth Sensation: 17 Wernicke s Area: 21, 22, 23, 25, 28 Blue Thread Surrounds Area of Tumor to be Removed Sylvian Fissure IMRI to Assess Extent of Resection Pre T1 With Gd Intraop T2 T1 With Gd 2 yrs After Surgery 9
10 45 y.o. man with new contrast enhancement 21 months after right frontal craniotomy T1 With Gd FLAIR With Gd Cortical Mapping Site of Surgery Performed 21 Months Previous to Present Surgery Silent Cortex (Sup. Frontal Gyrus) Letters (F, G, J, H, V, P, U, K, S, R, T, A) Motor Cortex (Precentral Gyrus) 7, Shoulder Motion; 4,2, & 1, Wrist Motion; 3 & 8, Finger Flexion Localize Tumor Margins In Relation to Motor Cortex Non-Ferromagnetic Bronze Probe 10
11 After Initial Tumor Resection IMRI to Detect Residual Tumor Pre T1 With Gd Intraop T1 Without Gd T1 With Gd After Medial Resection IMRI and Cortical Mapping Yr Sex Lobe(s) Dx WHO Motor Sensory Speech MR Complete Resection IMR Improved Resection Neuro Deficit Mixed Oligoastrocytoma 1 29 M Left frontal 3 Y Y Y N 1 Y N Rt frontoparietal 2 25 M GBM 4 Y Y N N 2 N N Lt temporal & Mixed Oligoastrocytoma 3 40 M insular 3 Y N Y N 3 Y Temporary Lt Anaplastic 4 27 F temporal astrocytoma 3 N Y Y Y Y Temporary Lt Anaplastic 5 57 F temporal astrocytoma 3 N N Y Y Y Temporary 6 49 M Rt parietal GBM 4 Y Y N Y N N 7 33 M Lt temporal DNET 1 Y Y Y Y Y N Rt frontal GBM 4 Y N N Y N N 8 54 F 9 45 M Mixed Oligoastrocytoma Rt frontal 3 Y N N Y Y N F Lt parietal GBM 4 N Y N Y Y N 1. Frozen section diagnosis was high grade glioma and tumor infiltrated deep white matter. 2. Tumor that infiltrated corticospinal tract in deep white matter was not removed. 3. Mass effect relieved; insular tumor not removed because patient was restless and frozen section diagnosis was high grade glioma. HIV(+) patient. From: Weingarten DM, et al. J Neurosurg 111(6): ,
12 Mapping in imri Suite vs. Standard OR Advantage of imri suite vs. Standard Neurosurgical OR Intraoperative evaluation of completeness of resection of tumors is possible in imri suite but not in conventional OR Recognize and remove residual tumor during the same procedure Improved resections may improve prognosis Disadvantages of imri suite vs. Standard Neurosurgical OR Scan time increases the duration of surgery; use preoperative MRI and frameless stereotaxy for centering incisions and locating the tumor eliminates initial imri scans immediately before surgery; prefer linear incisions to scalp flaps Head holders are less adjustable; positioning is less variable Table is more firm; need to place additional cushions Special safety considerations are required MR compatible instruments Avoid contact of coil to body and looping of wires Surgical navigation system in the intraoperative MRI suite eliminates the need for an initial imri scan and is useful in orienting anatomic relationships displayed on the radiographic images to the surgical exposure. Interventional MRI Advantages Intraoperative evaluation of completeness of resection of tumors Recognize residual tumor Resect residual tumor Improved resections may improve prognosis Evaluates for surgical complications that can be treated early Intracerebral hemorrhage Intraoperative confirmation of correct position of biopsy needles and intraventricular catheters. Well-suited for monitoring of intracerebral infusions Disadvantages Scan time increases the duration of surgery Higher costs Display of 3D image sets is not as straightforward as with frameless stereotactic systems Special safety considerations are required MR compatible instruments Avoid contact of coil to body Avoid looping of wires 5-Aminolevulinic acid (5-ALA) to highlight tumor Adjunct measure to identify more high-grade glioma tissue during the operative procedure Results in protoporphyrin accumulation in tumor Peak uptake 6 hours after oral administration Glioma visualized using filter on microscope Violet light visualize protoporphyrin IX Does not identify low-grade glioma Assessment improves removal of tumor from non-eloquent brain Phase III clinical trial of malignant glioma 322 patients* Microsurgery 5-ALA guided Gross total resection 36% 65% 6 m PFS 21% 41% No apparent affect on neurological funcron Preserves survival quality No difference in SAEs and AE between 2 groups *Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Aznella F, Reulen JH, ALA-Glioma Study Group: Fluorescenceguided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomized controlled multicenter phase III trial. Lancet Oncol 2006 May; 7(5): Fig. 3 Representative photographs showing cortical motor mapping (white circles), and 5-ALA fluorescence in glioblastoma showing tumor tissue under a white-light conditions and b illuminated with a blue filter. Orange fluorescence (Asterisk) is seen at the base of the resection cavity, indicatingresidual glioblastoma. 12
13 Immunotherapy Trials for GBM Activated lymphocytes freely enter and exit the CNS through the blood brain barrier. Immune checkpoint inhibitors, including 1) CTLA-4 (cytotoxic T-lymphocyte antigen 4) and 2) PD-1 (Programmed Death 1), suppress immune activation in tumors. Ipilimumab, a monoclonal antibody against CTLA4, received FDA approval in 2011 for treatment of metastatic melanoma Preusser M, Lim M, Hafler DA, Reardon DA, Sampson JH: Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol 11:504-14, 2015 Nivolumab and pembrolizumab, monoclonal antibodies inhibiting the PD1 receptor received FDA approval in 2014 for the treatment of malignant melanoma Ongoing clinical trials evaluating immune checkpoint inhibitors in glioblastoma include the Phase III trial NCT : Nivolumab (anti-pd1), Nivolumab + ipilimumab (anti- CTLA4), Bevacizumab (control group) for recurrent glioblastoma, n = 372 Laser Interstitial Thermal Therapy (LITT) Assessment: Surgical procedure (LITT) destroys tumor Rssue from non-eloquent brain areas Preserving neurological funcron 12% perm. neurologic deficit 3% vascular injury Preserving survival quality Temporary and permanent neurologic deficits? Removing maximal tumor from non-eloquent areas Limited to 1-2 cm radius? Complete excision with Grade I Tumors? Maximal cytoreduction with Grade II-IV (infiltrative) tumors Palliation?: Tumor tissue coagulated, not removed Perioperatively, LITT increases perilesional edema Long-term, similar or less mass effect after treatment Less invasive than craniotomy FIGURE 1. Laser ablation of 68-year-old man with recurrent glioblastoma pre-ablation (A) and post-ablation (B). Note that the ablation zone stops at the ambient cistern, sparing the adjacent brainstem. FIGURE 2. Laser ablation of a 45-year-old man with recurrent anaplastic oligodendroglioma pre-ablation (A) and post- ablation (B). The ablation zone conforms posteriorly to the precentral sulcus, avoiding injury to the primary motor cortex. Lee I, Kalkanis S, Hadjipanayis CG: Stereotactic laser interstitial thermal therapy for recurrent high-grade gliomas. Neurosurgery 79: , 2016 FIGURE 3. A 51-year-old man with distant right thalamic recurrence of a right temporal glioblastoma, pre-ablation (A) and post-ablation (B). Tumor Treating Electric Fields Randomized trial in GBM patients previously treated with chemoradiotherapy (median time from diagnosis to randomization of 3.8 months) Temozolamide vs. temozolomide + tumor treating fields (TTF): No placebo TTF delivered over 18 h/d to shaved scalp Planned interim analysis 105 patients with temozolomide 210 patients with temozolomide + TTF TMZ TMX + TTF Median PFS 4.0 m 7.1 m p= Median Survival 15.6 m 20.5 m p= % incidence of mild to moderate and 2% incidence of severe skin reaction (medical device site reaction beneath the transducer arrays) in patients treated with TTFields plus temozolomide. Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al.: Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA 314: , 2015 Electric fields disrupt cancer cell division Figures from: consultqd.clevelandclinic.org 13
14 Methods to Enhance Drug Delivery to the Tumor Drug delivery into brain tissue or lesion Convection- BBB Opening Enhanced Delivery During tissue infusion During opening of the BBB Systemic Chemotherapy Limited by the intact BBB MW of therapeutic agent Brain: Blood Concentration Hydrophilic compounds Hydrophobic compounds Large or small Large or small Small > 100 x systemic concentration 1 x systemic concentration < 1 x systemic concentration Enters CNS Enters CNS <<< 1 X systemic concentration Enters CNS Enters CNS < 1 x systemic concentration Distribution of Compound within CNS Volume of brain that can be treated Volume spreads radially from infusion site Volume of distribution in the arterial distributions injected with mannitol Entire CNS Large (4-8 cm3) Large (4-8 cm3) Large (entire brain) Speed of drug delivery into brain tissue or lesion Means of spread of drug Intracerebral Drug Delivery Techniques Convectionenhanced delivery Bolus intralesional therapy Slow-release polymer Hours to Days Seconds Days to Weeks Drug moves by bulk flow through the interstitial space Drug moves by diffusion along concentration gradients Drug moves by diffusion along concentration gradients Spread by MW Small=Large MW Small > Large MW Small > Large MW Variability of drug concentration Depth of Penetration of Drug Volume of brain that can be treated Homogeneous drug levels (1-100% of infused) within a brain volume High concentration at infusion point with steep fall off in concentration throughout the surrounding brain mm 1-4 mm 1-4 mm Large (4-8 cm3) Small (mm3) Small (mm3) High concentration around polymer with steep fall off in concentration throughout the surrounding brain Summary 1. Describe standard treatment for glioblastoma Maximal safe resection, concurrent TMZ and radiotherapy 2. Describe the impact of surgical neurological deficit and extent of resection on patient survival in glioblastoma Surgically-induced neurology deficit: Reduced survival quality and length Extent of resection: Improved survival quality and duration results from removal of maximal amount of tumor from non-eloquent areas 3. Describe the impact of functional brain mapping on surgical outcome and long-term prognosis in different types and grades of glioma Removing more tumor from non-eloquent brain areas should extend survival, especially in lower grade glioma Tumor in eloquent brain is not amenable to safe resection 4. Name a few agents and methods that are being tested in glioma clinical trials Laser Interstitial thermal therapy Intraoperative MRI guided glioma resection 5-ALA guided high-grade glioma resection Immune checkpoint modulators: Phase III Trial of Nivolumab, a mab inhibiting PD-1 receptor Tumor-treating electrical fields Methods to target chemotherapy to tumor tissue and reduce off-target effects Blood-brain barrier opening/convection-enhanced delivery/slow-release polymers 14
15 References 1. Duffau H: The reliability of asleep-awake-asleep protocol for intraoperative functional mapping and cognitive monitoring in glioma surgery. Acta Neurochir (Wien) 155:1803-4, Preusser M, Lim M, Hafler DA, Reardon DA, Sampson JH: Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol 11:504-14, Rodriguez A, Tatter SB, Debinski W: Neurosurgical Techniques for Disruption of the Blood- Brain Barrier for Glioblastoma Treatment. Pharmaceutics 7:175-87, Sanai N, Mirzadeh Z, Berger MS: Functional outcome after language mapping for glioma resection. N Engl J Med 358:18-27, Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-96, Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al.: Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA 314: , Vogelbaum MA, Aghi MK: Convection-enhanced delivery for the treatment of glioblastoma. Neuro Oncol 17 Suppl 2:ii3-ii8, Weingarten DM, Asthagiri AR, Butman JA, Sato S, Wiggs EA, Damaska B, Heiss JD: Cortical mapping and frameless stereotactic navigation in the high-field intraoperative magnetic resonance imaging suite. J Neurosurg 111: ,
SURGICAL MANAGEMENT OF BRAIN TUMORS
SURGICAL MANAGEMENT OF BRAIN TUMORS LIGIA TATARANU, MD, Ph D NEUROSURGICAL CLINIC, BAGDASAR ARSENI CLINICAL HOSPITAL BUCHAREST, ROMANIA SURGICAL INDICATIONS CONFIRMING HISTOLOGIC DIAGNOSIS REDUCING TUMOR
More informationMALIGNANT GLIOMAS: TREATMENT AND CHALLENGES
MALIGNANT GLIOMAS: TREATMENT AND CHALLENGES DISCLOSURE No conflicts of interest to disclose Patricia Bruns APRN, CNS Givens Brain Tumor Center Abbott Northwestern Hospital October 12, 2018 OBJECTIVES THEN
More informationPrimary low-grade brain tumors in
O R I G I N A L A R T I C L E S Copyright 2009, Barrow Neurological Institute Functional Cortical Mapping Using Subdural Grid Electrodes in Patients with Low-Grade Gliomas Presenting with Seizure Andrew
More informationRadioterapia no Tratamento dos Gliomas de Baixo Grau
Radioterapia no Tratamento dos Gliomas de Baixo Grau Dr. Luis Souhami University Montreal - Canada Low Grade Gliomas Relatively rare Heterogeneous, slow growing tumors WHO Classification Grade I Pilocytic
More informationSurgery Within and Around Critical White Matter Tracts
Surgery Within and Around Critical White Matter Tracts Kaisorn L. Chaichana, M.D. Assistant Professor of Neurosurgery, Oncology, and Otolaryngology-Head & Neck Surgery Mayo Clinic Florida, Jacksonville,
More informationClinical Management Protocol Chemotherapy [Glioblastoma Multiforme (CNS)] Protocol for Planning and Treatment
Protocol for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: GLIOBLASTOMA MULTIFORME (CNS) Patient information given at each stage following agreed
More informationIntraoperative perception and estimates on extent of resection during awake glioma surgery: overcoming the learning curve
CLINICAL ARTICLE J Neurosurg 128:1410 1418, 2018 Intraoperative perception and estimates on extent of resection during awake glioma surgery: overcoming the learning curve Darryl Lau, MD, 1 Shawn L. Hervey-Jumper,
More informationSmall and Big Operations: New Tools of the Trade for Brain Tumors. Disclosure. Incidence of Childhood Cancer
Small and Big Operations: New Tools of the Trade for Brain Tumors Nalin Gupta MD PhD Chief, Division of Pediatric Neurosurgery Departments of Neurosurgery and Pediatrics University of California San Francisco
More informationGlioblastoma: Adjuvant Treatment Abdulrazag Ajlan, MD, MSc, FRCSC, UCNS(D)
Glioblastoma: Adjuvant Treatment Abdulrazag Ajlan, MD, MSc, FRCSC, UCNS(D) *Neurosurgery Consultant, King Saud University, Riyadh, KSA *Adjunct Teaching Faculty, Neurosurgery, Stanford School Of Medicine,
More informationMedical Necessity Guideline
(MNG) Title: Electric Tumor Treatment Field Therapy MNG #: 003 SCO One Care Prior Authorization Needed? Yes No Clinical: Operational: Informational: Medicare Benefit: Yes No Last Revised Date: 1/25/2019;
More informationIntraoperative Monitoring: Role in Epilepsy Based Tumor Surgery December 2, 2012
Intraoperative Monitoring: Role in Epilepsy Based Tumor Surgery December 2, 2012 Aatif M. Husain, M.D. Duke University and Veterans Affairs Medical Centers, Durham, NC American Epilepsy Society Annual
More informationClinical Trials for Adult Brain Tumors - the Imaging Perspective
Clinical Trials for Adult Brain Tumors - the Imaging Perspective Whitney B. Pope, M.D., Ph.D. Department of Radiology David Geffen School of Medicine at UCLA August 22, 2015 1 Disclosure of Financial Relationships
More informationSurvival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy: A Retrospective Comparative Study
Original Article Research in Oncology June 2017; Vol. 13, No. 1: 18-22. DOI: 10.21608/resoncol.2017.552.1022 Survival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy:
More informationCarmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma
National Institute for Health and Clinical Excellence Health Technology Appraisal Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma Personal statement Conventional
More informationFACT SHEET. About Optune
About Optune Optune is the Tumor Treating Fields (TTFields) delivery system that is approved by the United States (US) Food and Drug Administration (FDA) for the treatment of adult patients with glioblastoma.
More informationSee the corresponding editorial in this issue, pp 1 2. J Neurosurg 115:3 8, An extent of resection threshold for newly diagnosed glioblastomas
See the corresponding editorial in this issue, pp 1 2. J Neurosurg 115:3 8, 2011 An extent of resection threshold for newly diagnosed glioblastomas Clinical article Nader Sanai, M.D., 1 Mei-Yin Polley,
More informationTHE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION. Mustafa Rashid Issa
THE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION Mustafa Rashid Issa ABSTRACT: Illustrate malignant tumors that form either in the brain or in the nerves originating in the brain.
More informationCorporate Medical Policy
Corporate Medical Policy Brachytherapy, Intracavitary Balloon Catheter for Brain Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: brachytherapy_intracavitary_balloon_catheter_for_brain_cancer
More information성균관대학교삼성창원병원신경외과학교실신경종양학 김영준. KNS-MT-03 (April 15, 2015)
성균관대학교삼성창원병원신경외과학교실신경종양학 김영준 INTRODUCTIONS Low grade gliomas (LGG) - heterogeneous group of tumors with astrocytic, oligodendroglial, ependymal, or mixed cellular histology - In adults diffuse, infiltrating
More informationPrecision medicine for gliomas
Precision medicine for YAZMIN ODIA, MD MS LEAD PHYSICIAN OF MEDICAL NEURO-ONCOLOGY DISCLOSURES Novocure: Advisory Board for Optune in No other financial conflicts of interest Glioma OVERVIEW INFILTRATIVE,
More informationCNS SESSION 3/8/ th Multidisciplinary Management of Cancers: A Case based Approach
CNS SESSION Chair: Ruben Fragoso, MD/PhD UC Davis Fellow: Michael Cardenas, MD UC Davis Panel: Gordon Li, MD Stanford Seema Nagpal, MD Stanford Jennie Taylor, MD UCSF HPI: 46 yo right handed woman who
More informationImaging for suspected glioma
Imaging for suspected glioma 1.1.1 Offer standard structural MRI (defined as T2 weighted, FLAIR, DWI series and T1 pre- and post-contrast volume) as the initial diagnostic test for suspected glioma, unless
More informationTreatment with Tumor-Treating Fields therapy and pulse dose bevacizumab in patients with bevacizumab-refractory recurrent glioblastoma: A case series.
School of Medicine Digital Commons@Becker Open Access Publications 2016 Treatment with Tumor-Treating Fields therapy and pulse dose bevacizumab in patients with bevacizumab-refractory recurrent glioblastoma:
More informationExamining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to.
Stratified Medicine Examining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to. Looking in detail at cancer cells and their genetic make up. Permit
More informationTania Kaprealian, M.D. Assistant Professor UCLA Department of Radiation Oncology August 22, 2015
Tania Kaprealian, M.D. Assistant Professor UCLA Department of Radiation Oncology August 22, 2015 Most common brain tumor, affecting 8.5-15% of cancer patients. Treatment options: Whole brain radiation
More informationContemporary Management of Glioblastoma
Contemporary Management of Glioblastoma Incidence Rates of Primary Brain Tumors Central Brain Tumor Registry of the United States, 1992-1997 100 Number of Cases per 100,000 Population 10 1 0.1 x I x I
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation
More informationSystemic Treatment. Third International Neuro-Oncology Course. 23 May 2014
Low-Grade Astrocytoma of the CNS: Systemic Treatment Third International Neuro-Oncology Course São Paulo, Brazil 23 May 2014 John de Groot, MD Associate Professor, Neuro-Oncology UT MD Anderson Cancer
More informationUpdate on Pediatric Brain Tumors
Update on Pediatric Brain Tumors David I. Sandberg, M.D. Director of Pediatric Neurosurgery & Associate Professor Dr. Marnie Rose Professorship in Pediatric Neurosurgery Pre-talk Questions for Audience
More informationLaser Interstitial Thermal Therapy (LITT) in Neuro-Oncology. Tim Lucas, MD, PhD Neurosurgery
Laser Interstitial Thermal Therapy (LITT) in Neuro-Oncology Tim Lucas, MD, PhD Neurosurgery Timothy.Lucas@uphs.upenn.edu 2016 Laser Interstitial Thermal Therapy (LITT) in Neuro-Oncology Tim Lucas, MD,
More informationRegional Neuro-Oncology Service Information Evening
Regional Neuro-Oncology Service Information Evening Dr Tom Flannery Information Evening hosted by Brainwaves NI, in partnership with the Northern Ireland Regional Neuro-Oncology Multi Disciplinary Team.
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM ANAPLASTIC GLIOMAS CNS Site Group Anaplastic Gliomas Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationUPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS
UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS Antonio M. Omuro Department of Neurology Memorial Sloan-Kettering Cancer Center II International Neuro-Oncology Congress Sao Paulo, 08/17/12 CHALLENGES IN
More informationClinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: PA.CP.MP.145
Clinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: PA.CP.MP.145 Effective Date: 01/18 Last Review Date: 04/18 Coding Implications Revision Log Description Electric tumor treating
More informationNOW WITH SYSTEM OVERVIEW MINIMALLY INVASIVE ROBOTIC LASER THERMOTHERAPY
NOW WITH SYSTEM OVERVIEW MINIMALLY INVASIVE ROBOTIC LASER THERMOTHERAPY Mini-Bolt Access Robotically Controlled Probe Driver MRI-Guided Laser Energy PRECISION AND CONFIDENCE DELIVERED THROUGH A MINIMALLY
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 27 May 2017 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Challenges in immunooncology
More informationjournals/eano/index.html Homepage: Online Database Featuring Author, Key Word and Full-Text Search
Volume 3 (2013) // Issue 2 // e-issn 2224-3453 Neurology Neurosurgery Medical Oncology Radiotherapy Paediatric Neurooncology Neuropathology Neuroradiology Neuroimaging Nursing Patient Issues Journey of
More informationDisclosures 2/10/2017. RAIN 2017 Difficult Cases Session. Patient MC, Original Diagnosis, 9/2006. MRI 9/5/06, pre-op
Disclosures RAIN 2017 Difficult Cases Session Clinical trials research funding support from: Novartis Genentech/Roche Merck NEUROLOGY AND NEUROLOGICAL SURGERY Jennifer L. Clarke, MD, MPH Associate Professor
More information21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare
Practice Changing Articles in Neuro Oncology for 2016/17 Disclosure No conflicts to declare Frances Cusano, BScPharm, ACPR April 21, 2017 Objectives Gliomas To describe the patient selection, methodology
More informationPlanning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement
Connelly et al. BMC Cancer (2016) 16:842 DOI 10.1186/s12885-016-2890-0 CASE REPORT Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement Jennifer
More informationPre-surgical planning for brain tumor resection using functional MRI
June 2011 Divya S Bolar, HMSIV Pre-surgical planning for brain tumor resection using functional MRI Divya S. Bolar,, HMS IV 1 Our patient: clinical history 85-year year-old right-handed handed woman presents
More informationGliomas account for 28% of the nearly 70,000 primary
See the corresponding editorial in this issue (E2). Neurosurg Focus 37 (6):E1, 2014 AANS, 2014 Stereotactic laser ablation of high-grade gliomas Ammar H. Hawasli, M.D., Ph.D., 1 Albert H. Kim, M.D., Ph.D.,
More informationSelecting the Optimal Treatment for Brain Metastases
Selecting the Optimal Treatment for Brain Metastases Clinical Practice Today CME Co-provided by Learning Objectives Upon completion, participants should be able to: Understand the benefits, limitations,
More informationNeurosurgical Management of Brain Tumours. Nicholas Little Neurosurgeon RNSH
Neurosurgical Management of Brain Tumours Nicholas Little Neurosurgeon RNSH General Most common tumours are metastatic 10x more common than primary Incidence of primary neoplasms is 20 per 100000 per year
More informationGeneral Identification. Name: 江 X X Age: 29 y/o Gender: Male Height:172cm, Weight: 65kg Date of admission:95/09/27
General Identification Name: 江 X X Age: 29 y/o Gender: Male Height:172cm, Weight: 65kg Date of admission:95/09/27 Chief Complaint Sudden onset of seizure for several minutes Present illness This 29-year
More informationImmunotherapy for the Treatment of Brain Metastases
Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Lawrence G. Lum, MD, DSc Karmanos Cancer Institute and Wayne State University Advances in Cancer Immunotherapy
More informationSociety for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases
Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Geoffrey T. Gibney, MD Georgetown-Lombardi Comprehensive Cancer Center Medstar-Georgetown University Hospital
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM LOW GRADE GLIOMAS CNS Site Group Low Grade Gliomas Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING
More informationComparison of conscious sedation and general anesthesia for motor mapping and resection of tumors located near motor cortex
Neurosurg Focus 15 (1):Article 8, 2003, Click here to return to Table of Contents Comparison of conscious sedation and general anesthesia for motor mapping and resection of tumors located near motor cortex
More informationPRESURGICAL PLANNING. Strongly consider neuropsychological evaluation before functional imaging study Strongly consider functional imaging study
NOTE: Consider Clinical Trials as treatment options for eligible patients. Page 1 of 6 RADIOLOGICAL PRESENTATION PRESURGICAL PLANNING TREATMENT Imaging study suggestive of glioma 1 Left hemisphere speech/motor
More informationUniversity of Zurich. Temozolomide and MGMT forever? Zurich Open Repository and Archive. Weller, M. Year: 2010
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich Year: 2010 Temozolomide and MGMT forever? Weller, M Weller, M (2010). Temozolomide and MGMT forever? Neuro-Oncology,
More informationFunctional Outcome after Language Mapping for Glioma Resection
T h e n e w e ng l a nd j o u r na l o f m e dic i n e original article Functional Outcome after Language Mapping for Glioma Resection Nader Sanai, M.D., Zaman Mirzadeh, Ph.D., and Mitchel S. Berger, M.D.
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: tumor_treatment_fields_therapy 9/2013 11/2017 11/2018 6/2018 Description of Procedure or Service Tumor-treatment
More informationDiffusion Tensor Imaging 12/06/2013
12/06/2013 Beate Diehl, MD PhD FRCP University College London National Hospital for Neurology and Neurosurgery Queen Square London, UK American Epilepsy Society Annual Meeting Disclosure None Learning
More informationRIGHT HEMISPHERE LANGUAGE MAPPING USING ELECTROCORTICAL STIMULATION IN PATIENTS WITH BILATERAL LANGUAGE
RIGHT HEMISPHERE LANGUAGE MAPPING USING ELECTROCORTICAL STIMULATION IN PATIENTS WITH BILATERAL LANGUAGE Rosette A. Jabbour, MD Gail L. Risse, PhD Patricia E. Penovich, MD Frank J. Ritter, MD John R. Gates,
More informationCURRENT CONTROVERSIES IN THE MANAGEMENT OF HIGH GRADE GLIOMAS: AN INTERACTIVE CASE DISCUSSION *
CURRENT CONTROVERSIES IN THE MANAGEMENT OF HIGH GRADE GLIOMAS: AN INTERACTIVE CASE DISCUSSION * Alessandro Olivi, MD, Jaishri Blakeley, MD, and Allen K. Sills, MD, FACS ABSTRACT The management of glioma
More informationConcepts for a personalized neurosurgical oncology. XXIV Annual Conference Pietro Paoletti 27. November 2015
Concepts for a personalized neurosurgical oncology Jörg-Christian Tonn Dept. of Neurosurgery Ludwig-Maximilian University München Großhadern Germany XXIV Annual Conference Pietro Paoletti 27. November
More informationJosh is JB s brother and caregiver.
PUT GBM ON PAUSE PUT LIFE ON PLAY Josh is JB s brother and caregiver. JB is an Optune user. OPTUNE + TMZ HAS BEEN PROVEN TO PROVIDE LONG-TERM QUALITY SURVIVAL TO PATIENTS WITH NEWLY DIAGNOSED GBM1,2,*
More informationSurgery for Medically Refractory Focal Epilepsy
Surgery for Medically Refractory Focal Epilepsy Seth F Oliveria, MD PhD The Oregon Clinic Neurosurgery Director of Functional Neurosurgery: Providence Brain and Spine Institute Portland, OR Providence
More informationNICE guideline Published: 11 July 2018 nice.org.uk/guidance/ng99
Brain tumours (primary) and brain metastases in adults NICE guideline Published: 11 July 2018 nice.org.uk/guidance/ng99 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationSeamless pre-surgical fmri and DTI mapping
Seamless pre-surgical fmri and DTI mapping Newest release Achieva 3.0T X-series and Eloquence enable efficient, real-time fmri for brain activity mapping in clinical practice at Nebraska Medical Center
More informationNewcastle Neuro-oncology Team Audit of Outcome of Glioblastoma Multiforme Chemoradiotherapy Treatment
Newcastle Neuro-oncology Team Audit of Outcome of Glioblastoma Multiforme Chemoradiotherapy Treatment Jennifer Wright Neurosurgery SSC Audit Team Jennifer Wright, Rachel Tresman, Cyril Dubois, Surash Surash,
More informationSYSTEM OVERVIEW MINIMALLY INVASIVE ROBOTIC LASER THERMOTHERAPY
SYSTEM OVERVIEW MINIMALLY INVASIVE ROBOTIC LASER THERMOTHERAPY Software NeuroBlate Fusion Software is the exclusive software intelligence behind the NeuroBlate System. NeuroBlate Fusion allows neurosurgeons
More informationIncidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide
405 Incidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide Walter Taal, MD 1 Dieta Brandsma, MD, PhD 1 Hein G. de Bruin, MD, PhD
More informationP. Hitchcock, Ph.D. Department of Cell and Developmental Biology Kellogg Eye Center. Wednesday, 16 March 2009, 1:00p.m. 2:00p.m.
Normal CNS, Special Senses, Head and Neck TOPIC: CEREBRAL HEMISPHERES FACULTY: LECTURE: READING: P. Hitchcock, Ph.D. Department of Cell and Developmental Biology Kellogg Eye Center Wednesday, 16 March
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 1 October 2016 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Immunology in the CNS
More informationCNS Tumors: The Med Onc Perspective. Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U.
CNS Tumors: The Med Onc Perspective Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U. Disclosure Speakers Bureau, Merck Basic Oncology Concepts Tissue Diagnosis Stage
More informationScottish Medicines Consortium
Scottish Medicines Consortium temozolomide 5, 20, 100 and 250mg capsules (Temodal ) Schering Plough UK Ltd No. (244/06) New indication: for the treatment of newly diagnosed glioblastoma multiforme concomitantly
More informationEpidemiology and Semiology of Tumor-based Epilepsy December 2, 2012
Epidemiology and Semiology of Tumor-based Epilepsy December 2, 2012 Charles J. Vecht, MD, PhD Medical Center The Hague SEIN Epilepsy Foundation, The Netherlands CHU Pitié-Salpêtrière, Paris, France American
More informationEPILEPSY 2018: UPDATE ON MODERN SURGICAL MANAGEMENT. Robert Kellogg, MD Advocate Children s Hospital Park Ridge, IL April 20, 2018
EPILEPSY 2018: UPDATE ON MODERN SURGICAL MANAGEMENT Robert Kellogg, MD Advocate Children s Hospital Park Ridge, IL April 20, 2018 No disclosures OBJECTIVES Brief history of epilepsy surgery Pre-operative
More informationInsulo-opercular Gliomas: Four Different Natural Progression Patterns and Implications for Surgical Indications
Neurol Med Chir (Tokyo) 50, 286 290, 2010 Insulo-opercular Gliomas: Four Different Natural Progression Patterns and Implications for Surgical Indications Ryuta SAITO, Toshihiro KUMABE, Masayuki KANAMORI,
More information11/27/2017. Modern Treatment of Meningiomas. Disclosures. Modern is Better? No disclosures relevant to this presentation
Modern Treatment of Meningiomas Michael A. Vogelbaum MD, PhD Professor of Neurosurgery Cleveland Clinic Disclosures No disclosures relevant to this presentation IP and royalties related to drug and device
More informationNeurosurgery Review. Mudit Sharma, MD May 16 th, 2008
Neurosurgery Review Mudit Sharma, MD May 16 th, 2008 Dr. Mudit Sharma, Neurosurgeon Manassas, Fredericksburg, Virginia http://www.virginiaspinespecialists.com Phone: 1-855-SPINE FIX (774-6334) Fundamentals
More informationTo achieve excellence in surgical neuro-oncology, the
CHAPTER 2 Defining and Achieving Excellence in Surgical Neuro-Oncology Mitchel S. Berger, MD To achieve excellence in surgical neuro-oncology, the neurosurgeon must achieve 3 particular things. The first
More informationXIXth Century: Localization of Functions to Different Parts of the Brain
XIXth Century: Localization of Functions to Different Parts of the Brain Studies by Bell and Magendie initiated an extremely important scientific procedure,, where a specific part of the nervous system
More informationIt s s Always Something!
It s s Always Something! New Approaches in Brain Tumor Treatment Virginia Stark-Vance, M.D. When Something Is a Brain Tumor Brain tumors aren t rare: there are over 100,000/yr Most originate as other cancers
More informationExam 1 PSYC Fall 1998
Exam 1 PSYC 2022 Fall 1998 (2 points) Briefly describe the difference between a dualistic and a materialistic explanation of brain-mind relationships. (1 point) True or False. George Berkely was a monist.
More informationHHS Public Access Author manuscript World Neurosurg. Author manuscript; available in PMC 2016 June 01.
Extra-operatve MRI (eomri) for Brain Tumor Surgery Initial Results at a Single Institution Muhammad M. Abd-El-Barr, MD, PhD a, Seth M. Santos, PA-C a, Linda S. Aglio, MD, MS b, Geoffrey S. Young, MD c,
More informationCitation Pediatrics international (2015), 57.
Title Long-term efficacy of bevacizumab a pediatric glioblastoma. Umeda, Katsutsugu; Shibata, Hirofum Author(s) Hiramatsu, Hidefumi; Arakawa, Yoshi Nishiuchi, Ritsuo; Adachi, Souichi; Ken-Ichiro Citation
More informationConcomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study T Sridhar 1, A Gore 1, I Boiangiu 1, D Machin 2, R P Symonds 3 1. Department of Oncology, Leicester
More informationAppraisal of carmustine. implants and temozolomide. for newly diagnosed high. Brain and Spine Foundation
Appraisal of carmustine implants and temozolomide for newly diagnosed high grade glioma Brain and Spine Foundation June 2005 Submission to the National Institute for Health and Clinical Excellence Brain
More informationELECTRIC TUMOR TREATMENT FIELDS
ELECTRIC TUMOR TREATMENT FIELDS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationBrain Tumors. Andrew J. Fabiano, MD FAANS. Associate Professor of Neurosurgery Roswell Park Cancer Institute SUNY at Buffalo School of Medicine
Brain Tumors Andrew J. Fabiano, MD FAANS Associate Professor of Neurosurgery Roswell Park Cancer Institute SUNY at Buffalo School of Medicine Brain Tumors Brain Tumor Basics Types of Tumors Cases Brain
More informationCURRICULUM VITAE Prof. Dr. med. Walter Stummer
CURRICULUM VITAE Prof. Dr. med. Walter Stummer Date of birth: April 19, 1964, in Düsseldorf, Germany Medical education: 1984-91: Medical School, Ludwig-Maximilians-University, Munich 1988-90: Doctoral
More informationCEREBRUM. Dr. Jamila EL Medany
CEREBRUM Dr. Jamila EL Medany Objectives At the end of the lecture, the student should be able to: List the parts of the cerebral hemisphere (cortex, medulla, basal nuclei, lateral ventricle). Describe
More informationCorporate Medical Policy Tumor-Treatment Fields Therapy for Glioblastoma
Corporate Medical Policy Tumor-Treatment Fields Therapy for Glioblastoma File Name: Origination: Last CAP Review: Next CAP Review: Last Review: tumor-treatment_fields_therapy_for_glioblastoma 9/2013 11/2017
More informationInvasive Evaluation for Epilepsy Surgery Lesional Cases NO DISCLOSURES. Mr. Johnson. Seizures at 29 Years of Age. Dileep Nair, MD Juan Bulacio, MD
Invasive Evaluation for Epilepsy Surgery Lesional Cases NO DISCLOSURES Dileep Nair, MD Juan Bulacio, MD Mr. Johnson Seizures at 29 Years of Age Onset of seizures at 16 years of age bed wetting episodes
More informationAMERICAN BRAIN TUMOR ASSOCIATION. Oligodendroglioma and Oligoastrocytoma
AMERICAN BRAIN TUMOR ASSOCIATION Oligodendroglioma and Oligoastrocytoma ACKNOWLEDGEMENTS ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the
More informationCorporate Medical Policy
Corporate Medical Policy BRAF Gene Variant Testing to Select Melanoma or Glioma Patients File Name: Origination: Last CAP Review: Next CAP Review: Last Review: braf_gene_variant_testing_to_select_melanoma_or_glioma_patients_for_targeted_
More informationApplication of Tumor Treating Fields for Newly Diagnosed Glioblastoma Multiforme: Understanding of National Practice Patterns and Trends
Application of Tumor Treating Fields for Newly Diagnosed Glioblastoma Multiforme: Understanding of National Practice Patterns and Trends Shearwood McClelland III, M.D. Department of Radiation Medicine
More informationBrain tumours (primary) and brain metastases in adults
Brain tumours (primary) and brain metastases in adults NICE guideline Draft for consultation, January 0 This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain
More informationOptimal Management of Isolated HER2+ve Brain Metastases
Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not
More informationAntibody-Drug Conjugates in Glioblastoma Multiforme: Finding Ways Forward
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationHSV1716 Dose levels and Cohort size Dose level No of Patients HSV1716 Dosage 1* 3 to 6 1 ml of 1 x 10 5 infectious units HSV1716 per ml 2
Abstract and Schema: Description and Rationale: Pediatric high grade gliomas have a progressive initial course and high risk of relapse/ progression; making the 5-year overall survival rate 15-35% with
More informationRetrospective Study of The Corticosteroids Administration in Glioblastoma Patients as A Prognostic Factor in The Disease
The Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (5), Page 4551-4555 Retrospective Study of The Corticosteroids Administration in Glioblastoma Patients as A Prognostic Factor in The Disease
More information3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors
research article 213 3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors Yilmaz Tezcan and Mehmet Koc Department
More informationOligodendrogliomas & Oligoastrocytomas
Oligodendrogliomas & Oligoastrocytomas ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit organization dedicated solely
More informationMorbidity of Stereotactic Biopsy for Intracranial Lesions
Kobe J. Med. Sci., Vol. 56, No. 4, pp. E148-E153, 2010 Morbidity of Stereotactic Biopsy for Intracranial Lesions MASAMITSU NISHIHARA 1 *, TAKASHI SASAYAMA 2, HIROSHI KUDO 3, and EIJI KOHMURA 2 1 Department
More informationIntensity modulated radiotherapy (IMRT) for treatment of post-operative high grade glioma in the right parietal region of brain
1 Carol Boyd March Case Study March 11, 2013 Intensity modulated radiotherapy (IMRT) for treatment of post-operative high grade glioma in the right parietal region of brain History of Present Illness:
More informationSupratentorial Glioblastoma Multiforme: The Role of Surgical Resection Versus Biopsy Among Older Patients
Ann Surg Oncol DOI 10.1245/s10434-010-1242-6 ORIGINAL ARTICLE NEURO-ONCOLOGY Supratentorial Glioblastoma Multiforme: The Role of Surgical Resection Versus Biopsy Among Older Patients Kaisorn L. Chaichana,
More information